MX2021003271A - Formulaciones de analogos del peptido similar a glucagon tipo 2 (glp-2). - Google Patents
Formulaciones de analogos del peptido similar a glucagon tipo 2 (glp-2).Info
- Publication number
- MX2021003271A MX2021003271A MX2021003271A MX2021003271A MX2021003271A MX 2021003271 A MX2021003271 A MX 2021003271A MX 2021003271 A MX2021003271 A MX 2021003271A MX 2021003271 A MX2021003271 A MX 2021003271A MX 2021003271 A MX2021003271 A MX 2021003271A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- analogues
- formulations
- liquid formulations
- glucagon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18197755.4A EP3628683A1 (en) | 2018-09-28 | 2018-09-28 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| PCT/EP2019/076305 WO2020065064A1 (en) | 2018-09-28 | 2019-09-27 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003271A true MX2021003271A (es) | 2021-05-12 |
Family
ID=63794308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003271A MX2021003271A (es) | 2018-09-28 | 2019-09-27 | Formulaciones de analogos del peptido similar a glucagon tipo 2 (glp-2). |
| MX2026000859A MX2026000859A (es) | 2018-09-28 | 2021-03-19 | Formulaciones de analogos del peptido similar a glucagon tipo 2 (glp-2) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2026000859A MX2026000859A (es) | 2018-09-28 | 2021-03-19 | Formulaciones de analogos del peptido similar a glucagon tipo 2 (glp-2) |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220265551A1 (https=) |
| EP (2) | EP3628683A1 (https=) |
| JP (2) | JP7566730B2 (https=) |
| KR (2) | KR20260008798A (https=) |
| CN (3) | CN112771073B (https=) |
| AU (1) | AU2019348538B2 (https=) |
| BR (1) | BR112021005858A2 (https=) |
| CA (1) | CA3114330A1 (https=) |
| CL (1) | CL2021000678A1 (https=) |
| IL (1) | IL281362B1 (https=) |
| MX (2) | MX2021003271A (https=) |
| NZ (1) | NZ775113A (https=) |
| SG (1) | SG11202102383VA (https=) |
| WO (1) | WO2020065064A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019026711A2 (pt) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| EP4154869A4 (en) * | 2020-05-22 | 2025-01-22 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glp-2 |
| MX2023006901A (es) * | 2020-12-16 | 2023-06-26 | Zealand Pharma As | Uso de analogos de glp-2 en pacientes con insuficiencia renal. |
| AU2022341538A1 (en) * | 2021-09-10 | 2024-04-11 | Zealand Pharma A/S | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| EP4572783A1 (en) | 2022-09-30 | 2025-06-25 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| WO2024075135A1 (en) * | 2022-10-03 | 2024-04-11 | Orbicular Pharmaceutical Technologies Private Limited | "stable injectable compositions of glp-2 peptide" |
| IL322328A (en) | 2023-01-27 | 2025-09-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| WO2025141129A1 (en) | 2023-12-28 | 2025-07-03 | Zealand Pharma A/S | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ250844A (en) * | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| DE60142885D1 (de) | 1996-04-12 | 2010-10-07 | Ontario Inc 1149336 | Dem Glukagon ähnliches Peptid-2 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| ATE396202T1 (de) | 2001-02-16 | 2008-06-15 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| EP2119724A1 (en) * | 2005-05-03 | 2009-11-18 | Novetide Ltd. | Solid-phase process foor the preparation of goserelin |
| DE602006020123D1 (de) * | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| CN101341254A (zh) * | 2005-12-24 | 2009-01-07 | 蒂加斯克乳制品研究中心 | 反-10，顺-12十八碳二烯酸的生产方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| AU2007319066B2 (en) * | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| WO2008082656A1 (en) * | 2006-12-29 | 2008-07-10 | Ipsen Pharma S.A.S. | Glp-1 pharmaceutical compositions |
| CA2798518A1 (en) * | 2010-05-17 | 2011-11-24 | Cebix, Inc. | Pegylated c-peptide |
| FR2994390B1 (fr) * | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| PT2922530T (pt) * | 2012-11-20 | 2016-12-22 | Fresenius Kabi Usa Llc | Formulações de acetato de caspofungina |
| AU2015335743B2 (en) * | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| EP4591853A1 (en) * | 2016-11-21 | 2025-07-30 | Amylyx Pharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
-
2018
- 2018-09-28 EP EP18197755.4A patent/EP3628683A1/en not_active Withdrawn
-
2019
- 2019-09-27 AU AU2019348538A patent/AU2019348538B2/en active Active
- 2019-09-27 JP JP2021517294A patent/JP7566730B2/ja active Active
- 2019-09-27 US US17/276,252 patent/US20220265551A1/en active Pending
- 2019-09-27 NZ NZ775113A patent/NZ775113A/en unknown
- 2019-09-27 CN CN201980063594.1A patent/CN112771073B/zh active Active
- 2019-09-27 CN CN202510255078.6A patent/CN120204366A/zh active Pending
- 2019-09-27 KR KR1020257041229A patent/KR20260008798A/ko active Pending
- 2019-09-27 CN CN202410277209.6A patent/CN118267455A/zh active Pending
- 2019-09-27 KR KR1020217010775A patent/KR20210069056A/ko not_active Ceased
- 2019-09-27 SG SG11202102383VA patent/SG11202102383VA/en unknown
- 2019-09-27 WO PCT/EP2019/076305 patent/WO2020065064A1/en not_active Ceased
- 2019-09-27 EP EP19773860.2A patent/EP3856766A1/en active Pending
- 2019-09-27 MX MX2021003271A patent/MX2021003271A/es unknown
- 2019-09-27 BR BR112021005858-3A patent/BR112021005858A2/pt unknown
- 2019-09-27 CA CA3114330A patent/CA3114330A1/en active Pending
-
2021
- 2021-03-09 IL IL281362A patent/IL281362B1/en unknown
- 2021-03-19 MX MX2026000859A patent/MX2026000859A/es unknown
- 2021-03-19 CL CL2021000678A patent/CL2021000678A1/es unknown
-
2023
- 2023-10-16 US US18/487,666 patent/US20240065978A1/en active Pending
-
2024
- 2024-07-26 JP JP2024120747A patent/JP7738136B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220265551A1 (en) | 2022-08-25 |
| CN118267455A (zh) | 2024-07-02 |
| EP3856766A1 (en) | 2021-08-04 |
| IL281362B1 (en) | 2026-03-01 |
| MX2026000859A (es) | 2026-03-02 |
| NZ775113A (en) | 2026-01-30 |
| JP2022502432A (ja) | 2022-01-11 |
| CA3114330A1 (en) | 2020-04-02 |
| EP3628683A1 (en) | 2020-04-01 |
| KR20260008798A (ko) | 2026-01-16 |
| JP7738136B2 (ja) | 2025-09-11 |
| AU2019348538B2 (en) | 2025-04-03 |
| JP2024156754A (ja) | 2024-11-06 |
| US20240065978A1 (en) | 2024-02-29 |
| BR112021005858A2 (pt) | 2021-07-27 |
| IL281362A (en) | 2021-04-29 |
| CL2021000678A1 (es) | 2021-08-06 |
| SG11202102383VA (en) | 2021-04-29 |
| CN120204366A (zh) | 2025-06-27 |
| CN112771073B (zh) | 2025-07-01 |
| WO2020065064A1 (en) | 2020-04-02 |
| KR20210069056A (ko) | 2021-06-10 |
| AU2019348538A1 (en) | 2021-05-20 |
| JP7566730B2 (ja) | 2024-10-15 |
| CN112771073A (zh) | 2021-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003271A (es) | Formulaciones de analogos del peptido similar a glucagon tipo 2 (glp-2). | |
| NI201800139A (es) | Formulación farmacéutica líquida estable | |
| MX2023007117A (es) | Formulacion liquida para preparar un vehiculo de suministro que comprende un polimero termosensible y un polimero sensible a iones. | |
| CO7111300A2 (es) | Formulación de anticuerpos | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
| BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
| BR112021023501A2 (pt) | Formulações estabilizadas contendo anticorpos anti-angptl3 | |
| JP2016196511A5 (https=) | ||
| AR018891A1 (es) | Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol | |
| CL2019000246A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| BR112015020707A2 (pt) | formulações transdermicas | |
| AR114325A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| CO2021013677A2 (es) | Proceso para la fabricación de extractos bacterianos estables y su uso como fármacos | |
| CO2019014671A2 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso | |
| MX2020008323A (es) | Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino. | |
| SA522431528B1 (ar) | نواتج تجفيد/محاليل من بوليميكسين و زيدوفودين | |
| CL2021000290A1 (es) | Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente | |
| PE20220383A1 (es) | Glicoproteinas sialiladas | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| BR112018004400A2 (pt) | composições de vacina vlp estabilizadas | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| MX2016012319A (es) | Formulaciones antihelminticas veterinarias estables. | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| MX384159B (es) | Formulaciones y métodos para el suministro vaginal de antiprogestinas. |